Aktis Oncology, Inc. (AKTS) Stock

Aktis Oncology, Inc. (AKTS) is a Healthcare stock trading at $26.94 (as of 2026-09-02), with a market capitalization of $1.44B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Aktis Oncology, Inc. is a clinical-stage oncology company developing targeted radiopharmaceutical therapies using miniprotein radioconjugates. Its programs include Nectin-4–directed AKY-1189 for locally advanced or metastatic urothelial cancer and other solid tumors, and B7-H3–directed AKY-2519 for solid tumors including prostate and lung cancer.

Understand Aktis Oncology, Inc.: how it makes money

Aktis Oncology builds targeted radiopharmaceutical drugs that attach to tumor markers and deliver radioactive isotopes directly to cancer cells. It is a pre-revenue clinical-stage company that funds development through collaboration milestones and equity raises rather than product sales.

All value sits in the pipeline. The profit model is a binary option on AKY-1189's clinical readouts; until approval, every dollar in is R&D spend and every 'revenue' line is a milestone payment, not product sales.

Business quality (Unprofitable): Pre-revenue clinical-stage biotech with a single lead asset; value is entirely optionality on trial outcomes and partnership economics.

Bull case

  • Multi-indication platform optionality: The miniprotein radioconjugate platform targets Nectin-4, a marker expressed in urothelial cancer, breast cancer, and other solid tumors, so a single successful readout could anchor a multi-product franchise rather than a one-off asset.

Bear case

  • No revenue, deep operating losses: With $0 product revenue this quarter and an operating margin of -854%, every dollar of cash goes to R&D and G&A, meaning the runway is fully dependent on continued external financing until a commercial product exists.
  • Binary single-asset risk: The investment case rests almost entirely on AKY-1189; a negative Phase 2 or Phase 3 readout would remove the core asset with no approved products to fall back on.
Valuation — source: SEC EDGAR (first-party)
Price$26.94
Market Cap$1.44B
Price / Book2.97
Price / Sales148.95
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$1.49M
Net Margin-2957.6%
Revenue Growth (YoY)111.4%
EPS Growth (YoY)-98.0%
FCF Growth (YoY)29.3%
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.6
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderMPM BIOIMPACT LLC ($86.51M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOMatthew Roden
CountryUS
IPO Date2026-01-09

Related Companies (Pharmaceutical Products; 8 comparable drugmakers)

  • Cypherpunk Technologies Inc. (CYPH)
  • Veradermics, Incorporated (MANE)
  • Relmada Therapeutics, Inc. (RLMD)
  • DiaMedica Therapeutics Inc. (DMAC)
  • NRx Pharmaceuticals, Inc. (NRXP)
  • PDS Biotechnology Corporation (PDSB)
  • Longeveron Inc. (LGVN)
  • RenovoRx, Inc. (RNXT)
AKTS earnings history · AKTS institutional & insider holders · AKTS KPIs & operating metrics · AKTS financials · AKTS investor presentations & press releases · AKTS SEC filings · AKTS peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-09-02.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.